{"groups":[{"description":"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.\n\nMobilization and SC Collection: MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.\n\nAmyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).\n\nConditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion \\>/= 3.5 x 10\\^6 CD34+ cells/kg IV Day 0.\n\nMaintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year.\n\nfilgrastim\n\ncyclophosphamide\n\ndexamethasone\n\nmelphalan\n\nthalidomide\n\nperipheral blood","id":"FG000","title":"Treatment"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Not protocol-specified"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Patient Refusal"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"}],"milestones":[{"achievements":[{"comment":"104 patients were registered, 93 of whom were eligible and analyzable.","groupId":"FG000","numSubjects":"93"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"73"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"}],"type":"NOT COMPLETED"}],"title":"PBSCC or Induction/PBSCC"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Not protocol-specified"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Patient Refusal"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Progression"}],"milestones":[{"achievements":[{"comment":"6 patients who completed PBSCC or Induction/PBSCC did not begin Transplant","groupId":"FG000","numSubjects":"67"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"46"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"NOT COMPLETED"}],"title":"Transplant"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"On treatment at time of analysis"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Not protocol-specified"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"}],"milestones":[{"achievements":[{"comment":"Only patients with High Risk MM or AL + MM were allowed to enroll to Maintenance treatment.","groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Maintenance"}]}